SEC Form 4 · accession 0001209191-18-059447
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Nov 16, 2018
Accepted (ET)
Nov 20, 2018 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 29, 2018 | G | 1,860 | $0.00 | D | 57,657 | D | |
| Common StockF2,F3,F4 | Nov 16, 2018 | S | 5,855 | $76.3051 | D | 171,127 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F5 | Nov 16, 2018 | S | 3,199 | $77.1132 | D | 167,928 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F6 | Nov 16, 2018 | S | 946 | $77.9278 | D | 166,982 | I | Held by the Popovits 2010 Trust |
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $75.61 to $76.59.
- F5Represents weighted average sale price. Actual sale prices ranged from $76.61 to $77.58.
- F6Represents weighted average sale price. Actual sale prices ranged from $77.61 to $78.21.